Melinta Therapeutics, Inc. (NASDAQ:MLNT)

6.95
Delayed Data
As of Apr 23
 -0.50 / -6.71%
Today’s Change
6.50
Today|||52-Week Range
24.25
-56.01%
Year-to-Date

Five Year Financial Summary

Total Revenue

Cash & Short Term Investments

Cash From Operations

All Currency in US Dollars4 Quarter
Trend
Quarter 1
2017
Quarter 2
2017
Quarter 3
2017
Quarter 4
2017
Revenue and IncomeNet Revenues4.9M860.0K1.7M4.2M
 
 
 
 
 
Depreciation And Amortization9.0K6.0K6.0K430.0K
 
 
 
 
 
 
Operating ExpensesGross Income----------
General Expenses24.2M13.2M12.2M48.5M
 
 
 
 
 
Research And Development15.4M8.5M4.4M11.6M
 
 
 
 
 
Total Operating Expenses24.2M13.2M12.3M48.9M
 
 
 
 
 
 
Non-Operating ExpensesOperating Income-19.3M-12.3M-10.5M-44.7M
 
 
 
 
 
Extraordinary Charge-3.6M------
 
 
Interest Expense On Debt243.0K226.0K208.0K1.9M
 
 
 
 
 
Other Expenses0.000.000.0027.7M
 
 
 
Income Taxes, Minority Interest and Extra ItemsPre-Tax Income-22.9M-12.3M-10.4M-18.8M
 
 
 
 
 
Preferred Dividend0.000.000.00-2.1M
 
 
Net Income-22.9M-12.3M-10.4M-18.8M
 
 
 
 
 
 
Shares To Calculate EPSShares To Calculate EPS10.5M10.5M10.5M14.1M
 
 
 
 
 
Shares To Calculate EPS Diluted10.5M10.5M10.5M14.1M
 
 
 
 
 
 
Earnings Per ShareEPS-$2.20-$1.15-$1.00-$1.48
 
 
 
 
 
EPS Diluted-$2.20-$1.15-$1.00-$1.48